Celcuity Inc. (CELC) - Q3 2025 10-Q Summary
Business Context and Reporting Period
Celcuity Inc. is a clinical-stage biotechnology company developing gedatolisib, a targeted therapy for solid tumors. This report covers the quarterly period ended September 30, 2025. The company has not generated revenue to date and remains focused on advancing its lead candidate through Phase 3 clinical trials (VIKTORIA-1 and VIKTORIA-2) and preparing for regulatory submission.
Key Financial Metrics
| Metric | Q3 2025 (3 Months) | Q3 2024 (3 Months) | YTD 2025 (9 Months) | YTD 2024 (9 Months) |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| Net Loss | $(43.8) million | $(29.8) million | $(126.1) million | $(75.1) million |
| Net Loss Per Share | $(0.92) | $(0.70) | $(2.81) | $(1.96) |
| Cash & Investments | $455.0 million (as of Sept 30, 2025) | |||
| Total Debt (Principal) | $331.3 million (Convertible Notes + Term Loans) | |||
| Operating Cash Flow (YTD) | $(116.9) million | $(55.7) million |
Material Changes vs. Prior Period
- Increased Operating Expenses: Total operating expenses rose 43% quarter-over-quarter to $42.8 million (from $30.1 million) and 60% year-over-year to $123.0 million (from $76.8 million). This increase is driven by higher R&D costs for clinical trials and commercial launch preparations, as well as a significant rise in stock-based compensation.
- Capital Raising Activities: In July 2025, the company completed a $91.6 million equity offering and a $194.9 million convertible notes offering. In September 2025, the company drew an additional $30.0 million under its Term D Loan facility.
- Debt Structure: Total liabilities increased significantly due to the issuance of $201.3 million in 2.750% Senior Convertible Notes due 2031 and the drawdown of the Term D Loan.
- Interest Expense: Interest expense increased 37% in Q3 and 57% YTD due to the new convertible notes and increased term loan balances.
Guidance, Outlook, and Management Commentary
- Clinical Milestones: The company announced positive topline data from the PIK3CA wild-type cohort of the VIKTORIA-1 Phase 3 trial, showing statistically significant improvements in progression-free survival (PFS). The PIK3CA mutant cohort is fully enrolled, with data expected in Q1/Q2 2026. The VIKTORIA-2 Phase 3 trial began enrolling in July 2025.
- Regulatory Path: The FDA granted Real-Time Oncology Review (RTOR) status. The company made its first NDA pre-submission in September 2025 and expects to complete the final NDA submission in Q4 2025.
- Liquidity Outlook: Management believes current cash, investments, and available borrowings will fund operations through 2027. The company has $220 million in incremental term loans available upon achieving specific clinical and revenue milestones.
- Risks: Key risks include the uncertainty of FDA approval, the ability to commercialize gedatolisib, and the impact of high indebtedness on cash flow. The company also notes risks related to FDA funding cuts and trade policy changes.
Investor Verification Checklist
- NDA Submission Timeline: Verify the company's ability to meet the Q4 2025 target for final NDA submission to the FDA.
- Debt Covenants: Review the specific liquidity covenants and milestone triggers in the Amended and Restated Loan Agreement to ensure compliance.
- Convertible Note Conversion: Monitor the stock price relative to the $51.30 conversion price of the new Senior Notes to assess potential dilution.
- Cash Burn Rate: Track the quarterly cash burn rate against the $455 million liquidity position to validate the "through 2027" runway estimate.
- Commercial Readiness: Assess the progress of commercial headcount additions and infrastructure build-out mentioned in the expense increases.